Küpper-Tetzel, Claus P.
Idris, Raja
Kessel, Johanna
Schüttfort, Gundolf
Hoehl, Sebastian
Kohmer, Niko
Graf, Christiana
Hogardt, Michael
Besier, Silke
Wichelhaus, Thomas A.
Vehreschild, Maria J. G. T.
Stephan, Christoph
Wetzstein, Nils
Funding for this research was provided by:
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Article History
Received: 13 March 2023
Accepted: 27 September 2023
First Online: 27 October 2023
Declarations
:
: Claus P. Küpper-Tetzel, Johanna Kessel, Niko Kohmer, Silke Besier, and Nils Wetzstein have nothing to disclose. Raja Idris received speaker fees from Tillotts Pharma GmbH. Gundolf Schüttfort received funding from Gilead Sciences and speaker fees from ViiV Healthcare, Bristol Meyer Squibb, MSD and Hormosan for participation in Advisory Boards, Data Safety and Monitoring Boards and for preparation of educational materials and lecturing fees. Christiana Graf received travel grands and fees for advisory board services from AbbVie Deutschland GmbH & Co and Gilead Sciences GmbH. Michael Hogardt reports grants from Mukoviszidose Institut gGmbH and the German Federal Ministry of Health, honoraria for lectures from the Landesärztekammer Hessen, bioMérieux, Pfizer Pharma and funding from Merck AG outside the submitted work. Sebastian Hoehl received study support from Roche diagnostics. Thomas A. Wichelhaus reports research grants from MSD, Deutsche Krebshilfe, as well as speaker fees and consulting honoraria from Insmed, Osartis, all outside the submitted work. Maria J.G.T. Vehreschild received research grants from 3M, Astellas Pharma, Biontech, DaVolterra, Evonik, Gilead Sciences, Glycom, Immunic, MaaT Pharma, Merck/MSD, Organobalance, Seres Therapeutics, Takeda Pharmaceutical, as well as speaker fees or consulting fees from Alb Fils Kliniken GmbH, Arderypharm, Astellas Pharma, Basilea, Bio-Mérieux, DaVolterra, Farmak International Holding GmbH, Ferring, Gilead Sciences, Immunic AG, MaaT Pharma, Merck/MSD, Pfizer, Roche, Organobalance, SocraTec R&D GmbH, Tillots Pharma GmbH. Christoph Stephan has received fees for lectures and/or advisory board services from Gilead sciences, Janssen-Cilag, MSD & ViiV healthcare, and travel grants for scientific conference attendance from Gilead, Janssen, and AbbVie.
: This study was approved by our local ethics committee under file number 20–1009.